Immune to Cancer: The CRI Blog
-
ASCO20 Update: Cellular Immunotherapies, Genomics, and COVID-19
Several promising cellular immunotherapies were discussed at ASCO20, including those for solid cancers; plus updates on the cancer…
-
Building a Single-Cell Atlas with Dr. Ansuman Satpathy
Dr. Ansuman Satpathy is building a single-cell atlas to help us better understand why immunotherapy succeeds or…
-
How Immunotherapy Is Transforming Bladder Cancer Treatment
Arjun V. Balar, MD, discusses checkpoint immunotherapy, new FDA approvals, promising new therapies, and clinical trials for…
-
Analytical Strategies in Immunology for Cancer and COVID-19 with Dr. Katie Campbell
Dr. Campbell’s work as a CRI fellow at UCLA is improving our understanding of both cancer and…
-
AACR20 Day 2 Highlights: COVID-19, Adoptive Cell Therapy, and Checkpoint Immunotherapy Insights
The second day of AACR’s annual meeting heard from experts at cancer centers in COVID-19 hotspots around…
-
AACR20 Day 1 Highlights: Breast Cancer, Lung Cancer, and the Microbiome
The first day of the 2020 AACR Annual Meeting shared latest data from immunotherapy clinical trials in…
-
How Immunotherapy for Esophageal Cancer is Making an Impact
Dr. Deirdre Cohen discusses recent advances in immunotherapy for esophageal cancer, including biomarkers, checkpoint inhibitors, cell-based therapies,…
-
Defining Resistance to Treatment with Anti-PD-1/PD-L1 Immunotherapy
CRI's Vanessa M. Lucey, Ph.D, MBA, helps guide the design and analysis of future clinical trials involving…
-
CICON19 Day 1 Update: Cancer Prevention and Combination Immunotherapy Strategies
Day 1 of CICON19 explored how checkpoint immunotherapy might be improved through combination strategies as well as…